Use of ibrutinib as "bridging" for allogeneic hematopoietic stem cell transplantation from haploidentic donor and subsequent therapy of residual disease after transplantation in a patient with highly adverse mantle cell lymphoma
2019
Abstract
Mantle cell lymphoma (MCL) belongs to the group of aggressive non-Hodgkin's B lymphomas. Its course may be variable depending on the presence of risk factors, adverse forms are aggressive.
Intensive induction regimens based on chemoimmunotherapy and autologous haematopoietic stem cell transplantation are very effective, but sooner or later relapses occur, the treatment of which is much more problematic. Significant advances in this field have been the introduction of new drugs, including in particular Bruton Tyrosine Kinase (BTKi) inhibitors or Bcl-2 venetoclax inhibitor.